Does the media prefer ELAN or ARQT?

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 14 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.36 beat Arcutis Biotherapeutics' score of 1.15 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARQT or AXSM?

In the previous week, Axsome Therapeutics had 19 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 34 mentions for Axsome Therapeutics and 15 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Axsome Therapeutics' score of 0.94 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 21 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ARQT or RDY?

Arcutis Biotherapeutics currently has a consensus target price of $35.57, suggesting a potential upside of 49.59%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.67 Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor ARQT or RDY?

In the previous week, Arcutis Biotherapeutics had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 4 mentions for Dr. Reddy's Laboratories. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARQT or CRNX?

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 10 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Arcutis Biotherapeutics' score of 1.15 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ARQT or LNTH?

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Lantheus. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 9 mentions for Lantheus. Lantheus' average media sentiment score of 1.37 beat Arcutis Biotherapeutics' score of 1.15 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Arcutis Biotherapeutics (ARQT) Competitors

$23.78 -1.09 (-4.38%)

As of 08/28/2026 04:00 PM Eastern

Compare

ARQT vs. ELAN, AXSM, RDY, CRNX, and LNTH

Should you buy Arcutis Biotherapeutics stock or one of its competitors? Arcutis Biotherapeutics's main competitors and comparable companies include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), and Lantheus (LNTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Elanco Animal Health. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 14 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.36 beat Arcutis Biotherapeutics' score of 1.15 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has a net margin of 6.15% compared to Elanco Animal Health's net margin of -3.96%. Arcutis Biotherapeutics' return on equity of 15.05% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Elanco Animal Health has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Arcutis Biotherapeutics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.56	-$232M	-$0.41	N/A
Arcutis Biotherapeutics	$376.07M	7.95	-$16.14M	$0.21	113.24

Elanco Animal Health currently has a consensus target price of $29.09, indicating a potential upside of 20.41%. Arcutis Biotherapeutics has a consensus target price of $35.57, indicating a potential upside of 49.59%. Given Arcutis Biotherapeutics' higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Arcutis Biotherapeutics beats Elanco Animal Health on 10 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

Arcutis Biotherapeutics currently has a consensus price target of $35.57, suggesting a potential upside of 49.59%. Axsome Therapeutics has a consensus price target of $267.60, suggesting a potential upside of 34.46%. Given Arcutis Biotherapeutics' higher probable upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Arcutis Biotherapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

In the previous week, Axsome Therapeutics had 19 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 34 mentions for Axsome Therapeutics and 15 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Axsome Therapeutics' score of 0.94 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	21 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.95	-$16.14M	$0.21	113.24
Axsome Therapeutics	$638.50M	16.33	-$183.17M	-$3.75	N/A

81.5% of Axsome Therapeutics shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Axsome Therapeutics' net margin of -24.68%. Arcutis Biotherapeutics' return on equity of 15.05% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

Summary

Arcutis Biotherapeutics beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

In the previous week, Arcutis Biotherapeutics had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 4 mentions for Dr. Reddy's Laboratories. Arcutis Biotherapeutics' average media sentiment score of 1.15 beat Dr. Reddy's Laboratories' score of 0.59 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dr. Reddy's Laboratories has higher revenue and earnings than Arcutis Biotherapeutics. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.95	-$16.14M	$0.21	113.24
Dr. Reddy's Laboratories	$3.58B	2.84	$456M	$0.44	27.66

Arcutis Biotherapeutics currently has a consensus target price of $35.57, suggesting a potential upside of 49.59%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Arcutis Biotherapeutics' net margin of 6.15%. Arcutis Biotherapeutics' return on equity of 15.05% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Summary

Arcutis Biotherapeutics beats Dr. Reddy's Laboratories on 11 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Crinetics Pharmaceuticals?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Arcutis Biotherapeutics' return on equity of 15.05% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Arcutis Biotherapeutics presently has a consensus price target of $35.57, suggesting a potential upside of 49.59%. Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 4.53%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Arcutis Biotherapeutics has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.95	-$16.14M	$0.21	113.24
Crinetics Pharmaceuticals	$7.70M	1,168.70	-$465.32M	-$5.04	N/A

In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 10 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Arcutis Biotherapeutics' score of 1.15 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Arcutis Biotherapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market.

Summary

Arcutis Biotherapeutics beats Crinetics Pharmaceuticals on 13 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Lantheus?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Lantheus. MarketBeat recorded 15 mentions for Arcutis Biotherapeutics and 9 mentions for Lantheus. Lantheus' average media sentiment score of 1.37 beat Arcutis Biotherapeutics' score of 1.15 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics currently has a consensus price target of $35.57, indicating a potential upside of 49.59%. Lantheus has a consensus price target of $108.11, indicating a potential upside of 7.29%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lantheus has higher revenue and earnings than Arcutis Biotherapeutics. Lantheus is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	7.95	-$16.14M	$0.21	113.24
Lantheus	$1.56B	4.23	$233.56M	$4.14	24.34

Arcutis Biotherapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market.

99.1% of Lantheus shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lantheus has a net margin of 17.69% compared to Arcutis Biotherapeutics' net margin of 6.15%. Lantheus' return on equity of 28.10% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Lantheus	17.69%	28.10%	14.35%

Summary

Arcutis Biotherapeutics and Lantheus tied by winning 8 of the 16 factors compared between the two stocks.

Get Arcutis Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARQT vs. The Competition

Export

Metric	Arcutis Biotherapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.13B	$12.17B	$7.23B	$12.94B
Dividend Yield	N/A	2.62%	2.54%	11.02%
P/E Ratio	113.24	787.65	273.45	25.45
Price / Sales	7.95	760.81	621.81	95.39
Price / Cash	N/A	95.73	79.29	54.21
Price / Book	13.59	11.97	12.97	6.14
Net Income	-$16.14M	$2.83B	$3.48B	$348.86M
7 Day Performance	-5.18%	0.40%	0.13%	-0.80%
1 Month Performance	-14.64%	6.25%	8.37%	5.56%
1 Year Performance	53.22%	5.95%	24.55%	15.57%

Arcutis Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARQT Arcutis Biotherapeutics	4.1359 of 5 stars	$23.78 -4.4%	$35.57 +49.6%	+53.5%	$3.13B	$376.07M	113.24	150	News Coverage Insider Trade
ELAN Elanco Animal Health	4.6996 of 5 stars	$24.99 -0.3%	$29.09 +16.4%	+30.8%	$12.48B	$5.02B	N/A	9,400	Positive News
AXSM Axsome Therapeutics	4.2577 of 5 stars	$207.02 -0.1%	$267.60 +29.3%	+63.5%	$10.85B	$776.57M	N/A	380	News Coverage Analyst Revision
RDY Dr. Reddy's Laboratories	1.7864 of 5 stars	$12.21 -0.1%	N/A	-14.5%	$10.18B	$3.58B	27.73	27,527	News Coverage Analyst Upgrade
CRNX Crinetics Pharmaceuticals	1.6775 of 5 stars	$84.86 +0.0%	$81.00 -4.5%	+176.8%	$9.00B	$42.16M	N/A	210	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARQT) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. ELAN, AXSM, RDY, CRNX, and LNTH

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Summary

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Summary

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Arcutis Biotherapeutics compare to Crinetics Pharmaceuticals?

Summary

How does Arcutis Biotherapeutics compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. ELAN, AXSM, RDY, CRNX, and LNTH

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Do institutionals and insiders have more ownership in ELAN or ARQT?

Does the media prefer ELAN or ARQT?

Is ELAN or ARQT more profitable?

Which has more risk and volatility, ELAN or ARQT?

Which has preferable earnings and valuation, ELAN or ARQT?

Do analysts prefer ELAN or ARQT?

Summary

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Do analysts prefer ARQT or AXSM?

Which has more volatility and risk, ARQT or AXSM?

Does the media refer more to ARQT or AXSM?

Which has stronger valuation and earnings, ARQT or AXSM?

Do institutionals and insiders hold more shares of ARQT or AXSM?

Is ARQT or AXSM more profitable?

Summary

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Does the media favor ARQT or RDY?

Which has more volatility and risk, ARQT or RDY?

Do insiders & institutionals have more ownership in ARQT or RDY?

Which has higher valuation and earnings, ARQT or RDY?

Do analysts prefer ARQT or RDY?

Is ARQT or RDY more profitable?

Summary

How does Arcutis Biotherapeutics compare to Crinetics Pharmaceuticals?

Is ARQT or CRNX more profitable?

Do analysts prefer ARQT or CRNX?

Do institutionals & insiders hold more shares of ARQT or CRNX?

Which has stronger valuation & earnings, ARQT or CRNX?

Does the media refer more to ARQT or CRNX?

Which has more volatility and risk, ARQT or CRNX?

Summary

How does Arcutis Biotherapeutics compare to Lantheus?

Does the media favor ARQT or LNTH?

Do analysts rate ARQT or LNTH?

Which has higher valuation and earnings, ARQT or LNTH?

Which has more volatility and risk, ARQT or LNTH?

Do institutionals & insiders believe in ARQT or LNTH?

Is ARQT or LNTH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools